Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial-Reference-Cited by-同舟云学术

Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial

Published:2020-02-08 Issue:2 Volume:38 Page:507-514
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Cao Jun,Ouyang Quchang,Wang Shusen,Ragaz Joseph,Wang Xiaojia,Teng Yuee,Wang Biyun,Wang Zhonghua,Zhang Jian,Wang Leiping,Wu Jiong,Shao Zhimin,Hu Xichun

Funder

MSD China Holding Co., Ltd.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-020-00903-8.pdf

Reference34 articles.

1. Hesketh PJ (1999) Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist. 4:191–196

2. Sommariva S, Pongiglione B, Tarricone R (2016) Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review. Crit Rev Oncol Hematol 99:13–36

3. Hesketh PJ, Bohlke K, Lyman GH et al (2016) Antiemetics: American Society of Clinical Oncology focused guideline update. Am Soc Clin Oncol J Clin Oncol 34(4):381–386